— If 510(k) cleared, this next-generation investigational inhaled nitric oxide delivery system would be the latest in a long line of dual channel delivery systems building on Company’s dedication to meeting clinicians’ evolving needs — DUBLIN, Sept. 28, 2022 /PRNewswire/ — Mallinckrodt plc (OTCMKTS: MNKPF), a […]
Regulatory
FDA Clears DyAnsys Neurostimulation Device Primary Relief to Treat Post-Cardiac Surgery Pain
PALO ALTO, Calif., Sept. 22, 2022 /PRNewswire/ — DyAnsys, Inc., has announced that Primary Relief, a percutaneous electrical neurostimulation device, has been approved to treat pain following a cardiac surgery. The percutaneous electrical nerve stimulator (PENS) system can be used for up […]
Medtronic receives FDA clearance for expanded indication of LINQ II™ insertable cardiac monitor for use in pediatric patients ages 2 and older
The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population DUBLIN, Sept. 20, 2022 /PRNewswire/ — Medtronic plc ( NYSE:MDT), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Monitor (ICM) […]
Advanced NanoTherapies’ SirPlux Duo Drug-Coated Balloon Receives FDA Breakthrough Designation for Small Vessel Coronary Artery Disease
Breakthrough Designation Reinforces Significant Unmet Need in Treatment of Small Vessel Coronary Arteries LOS GATOS, Calif., Sept. 19, 2022 /PRNewswire/ — Advanced NanoTherapies, Inc., a privately-held medical device company committed to solving vascular disease’s most significant challenges through the creative applications of nanotechnology, […]
MagicTouch SCB receives IDE approval for In-Stent Restenosis indication
TAMPA, Fla., Sept. 17, 2022 /PRNewswire/ — The US FDA has granted an Investigational Device Exemption (IDE) approval for MagicTouch Sirolimus Coated Balloon (SCB) indicated for In-Stent Restenosis (ISR). US FDA’s IDE approval allows the MagicTouch SCB to be used in a pivotal clinical study to support […]
FDA Approves RECOVER IV Randomized Controlled Trial with Exception from Informed Consent (EFIC)
FDA Also Approves and Closes RECOVER III Post-Approval Study DANVERS, Mass.–(BUSINESS WIRE)–Abiomed (Nasdaq: ABMD) announces two approvals from the U.S. Food and Drug Administration (FDA) related to clinical research of Impella heart pumps in acute myocardial infarction (AMI) cardiogenic shock patients. […]
EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION
IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ — Edwards Lifesciences Corporation ( NYSE: EW), today announced the company’s PASCAL Precision transcatheter valve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR). “Patients suffering with debilitating […]
ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors
HALIFAX, Nova Scotia, Sept 12, 2022 – ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients […]
EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL
IRVINE, Calif., Sept. 12, 2022 /PRNewswire/ — Edwards Lifesciences ( NYSE: EW) today announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards’ breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve. The launch follows recent […]
Anthos Therapeutics Announces that Abelacimab Has Received FDA Fast Track Designation for the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation
This is the second Fast Track designation issued by the FDA for abelacimab Abelacimab is a dual-acting, once-monthly, fully human monoclonal antibody targeting both Factor XI and Factor XIa with high affinity and selectivity CAMBRIDGE, Mass., Sept. 08, 2022 (GLOBE NEWSWIRE) […]